These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1077 related items for PubMed ID: 29252091

  • 1. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V, Vysloužilová D, Uher M.
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M.
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL, Quaranta-El Maftouhi M, Mauget-Faÿsse M.
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [Abstract] [Full Text] [Related]

  • 7. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Reibaldi M, Boscia F, Avitabile T, Uva MG, Russo A, Zagari M, Occhipinti F, Russo V, Reibaldi A, Longo A.
    Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Photodynamic therapy for chronic central serous chorioretinopathy.
    Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, Gómez-Ulla F.
    Acta Ophthalmol; 2010 May; 88(3):371-6. PubMed ID: 19958296
    [Abstract] [Full Text] [Related]

  • 19. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [Abstract] [Full Text] [Related]

  • 20. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF, Espinoza JV.
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.